×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
REGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/15
11:06 am
regn
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]
Low
Report
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]
1/15
06:42 am
regn
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]
Low
Report
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]
1/14
07:36 pm
regn
BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]
Low
Report
BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]
1/14
03:53 am
regn
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]
Low
Report
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]
1/13
07:52 pm
regn
Regeneron CEO: AI is as good as the data it can train on [CNBC]
Low
Report
Regeneron CEO: AI is as good as the data it can train on [CNBC]
1/13
10:20 am
regn
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]
Low
Report
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]
1/11
08:40 pm
regn
A big Wall Street flip just changed the Regeneron narrative [Yahoo! Finance]
Medium
Report
A big Wall Street flip just changed the Regeneron narrative [Yahoo! Finance]
1/10
05:43 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
10/28/2025
06:30 am
REGN
regeneron pharmaceuticals, inc.
BEAT
Report
8.5%
regeneron pharmaceuticals, inc.
8/1/2025
06:30 am
REGN
regeneron pharmaceuticals, inc.
BEAT
Report
2.5%
regeneron pharmaceuticals, inc.
4/29/2025
06:30 am
REGN
regeneron pharmaceuticals, inc.
BEAT
Report
0.2%
regeneron pharmaceuticals, inc.
2/4/2025
06:30 am
REGN
regeneron pharmaceuticals, inc.
BEAT
Report
4.6%
regeneron pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
06:48 am
regn
Form 8-K REGENERON PHARMACEUTICAL For: Jan 12
Medium
Report
Form 8-K REGENERON PHARMACEUTICAL For: Jan 12
1/8
04:03 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Jan 07 Filed by: Bassler Bonnie L
Low
Report
Form 4 REGENERON PHARMACEUTICAL For: Jan 07 Filed by: Bassler Bonnie L
1/7
12:03 pm
regn
Form 144 REGENERON PHARMACEUTICAL Filed by: Bassler Bonnie L
Low
Report
Form 144 REGENERON PHARMACEUTICAL Filed by: Bassler Bonnie L
1/6
04:21 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Zoghbi Huda Y
Medium
Report
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Zoghbi Huda Y
1/6
04:18 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Thompson Craig B.
Medium
Report
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Thompson Craig B.
1/6
04:16 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Guarini Kathryn
Medium
Report
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Guarini Kathryn
1/6
04:16 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: SING GEORGE L
Medium
Report
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: SING GEORGE L
1/6
04:14 pm
regn
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Schenkein David P
Medium
Report
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Schenkein David P
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
7.4%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
TOP News Decliners
3/19
Coronavirus Proves Drug Companies To Be Innovators [Forbes]
-10.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: